Skip to Content

'
Michael Z. Gilcrease, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1991 Vanderbilt Medical School, Nashville, TN, MD, Medicine
1989 Vanderbilt Graduate School, Nashville, TN, PHD, Pathology
1984 Yale College, New Haven, CT, BA, Religious studies

Postgraduate Training

1994-1995 Clinical Fellowship, Surgical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
1991-1994 Clinical Residency, Anatomic Pathology, Baylor College of Medicine, Houston, TX

Board Certifications

1997 Cytopathology, American Board of Pathologists
1994 Anatomic Pathology, American Board of Pathologists

Selected Publications

Peer-Reviewed Original Research Articles

1. Huo L, Gong Y, Guo M, Gilcrease MZ, Wu Y, Zhang H, Zhang J, Resetkova E, Hunt KK, Deavers MT. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. Histopathology 67(2):245-54, 8/2015. e-Pub 2/2015. PMID: 25564996.
2. Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol 26(7):1346-52, 7/2015. e-Pub 4/2015. PMID: 25878190.
3. Eghtedari M, Dogan BE, Gilcrease M, Roberts J, Cook ED, Yang WT. Imaging and pathologic characteristics of breast amyloidosis. Breast J 21(2):197-9, Mar-Apr, 3/2015. e-Pub 1/2015. PMID: 25585499.
4. Lawton TJ, Acs G, Argani P, Farshid G, Gilcrease M, Goldstein N, Koerner F, Rowe JJ, Sanders M, Shah SS, Reynolds C. Interobserver variability by pathologists in the distinction between cellular fibroadenomas and phyllodes tumors. Int J Surg Pathol. e-Pub 8/2014.
5. Dave B, Granados-Principal S, Zhu R, Benz S, Rabizadeh S, Soon-Shiong P, Yu KD, Shao Z, Li X, Gilcrease MZ, Lai Z, Chen Y, Huang TH, Shen H, Liu X, Ferrari M, Zhan M, Wong ST, Kumaraswami M, Mittal V, Chen X, Gross SS, Chang JC. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proc Natl Acad Sci USA 111(24):8838-43, 2014.
6. Nayak A, Carkaci S, Gilcrease MZ, Liu P, Middleton LP, Bassett RL, Zhang J, Zhang H, Coyne RL, Bevers TB, Sneige N, Huo L. Benign papillomas without atypia diagnosed on core needle biopsy: experience from a single institution and proposed criteria for excision. Clin Breast Cancer 13(6):439-49, 12/2013. e-Pub 10/2013. PMID: 24119786.
7. Krishnamurthy S, Mathews K, McClure S, Murray M, Gilcrease M, Albarracin C, Spinosa J, Chang B, Ho J, Holt J, Cohen A, Giri D, Garg K, Bassett RL, Liang K. Multi-institutional comparison of whole slide digital imaging and optical microscopy for interpretation of hematoxylin-eosin-stained breast tissue sections. Arch Pathol Lab Med 137(12):1733-9, 12/2013. e-Pub 8/2013. PMID: 23947655.
8. Nayak A, Wu Y, Gilcrease MZ. Primary squamous cell carcinoma of the breast: predictors of locoregional recurrence and overall survival. Am J Surg Pathol 37(6):867-73, 6/2013. PMID: 23629447.
9. Huo L, Zhang J, Gilcrease MZ, Gong Y, Wu Y, Zhang H, Resetkova E, Hunt KK, Deavers MT. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology 62(2):267-74, 1/2013. e-Pub 9/2012. PMCID: PMC3881372.
10. de la Cruz J, Andre F, Harrell RK, Bassett RL, Arun B, Mathieu MC, Delaloge S, Gilcrease MZ. Tissue-based Predictors of Germline BRCA1 Mutations: Implications for Triaging of Genetic Testing. Hum Pathol 43(11):1932-39, 11/2012. e-Pub 5/2012. PMID: 22591913.
11. Alvarado R, Yi M, Le-Petross H, Gilcrease MZ, Mittendorf EA, Bedrosian I, Hwang RF, Caudle AS, Babiera GV, Akins JS, Kuerer HM, Hunt KK. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol 19(10):3177-84, 10/2012. e-Pub 7/2012. PMID: 22772869.
12. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol 36(9):1353-8, 9/2012. PMID: 22895267.
13. Smith TB, Gilcrease MZ, Santiago L, Hunt KK, Yang WT. Imaging features of primary breast sarcoma. AJR Am J Roentgenol 198(4):W386-93, 4/2012. PMID: 22451578.
14. Lester TR, Hunt KK, Nayeemuddin KM, Bassett RL, Gonzalez-Angulo AM, Feig BW, Huo L, Rourke LL, Davis WG, Valero V, Gilcrease MZ. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat 131(1):41-8, 1/2012. e-Pub 2/2011. PMCID: PMC3867807.
15. Wahbah MM, Gilcrease MZ, Wu Y. Lipomatous variant of myofibroblastoma with epithelioid features: a rare and diagnostically challenging breast lesion. Ann Diagn Pathol 15(6):454-8, 12/2011. e-Pub 10/2010. PMID: 21036082.
16. Perry KD, Reynolds C, Rosen DG, Edgerton ME, T Albarracin C, Gilcrease MZ, Sahin AA, Abraham SC, Wu Y. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma. Histopathology 59(4):619-30, 10/2011. PMID: 22014043.
17. Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton L, Sahin A, Xing Y, Hunt KK, Chen J, Bu H, Rashid A, Abraham SC, Wu Y. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol 42(8):1169-77, 8/2011. e-Pub 2/2011. PMID: 21334720.
18. Tang F, Wei B, Tian Z, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Zhang H, Sahin A, Chen J, Bu H, Abraham S, Wu Y. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology 59(1):106-15, 7/2011. e-Pub 6/2011. PMID: 21668471.
19. Carkaci S, Lane DL, Gilcrease MZ, Conrow D, Schwartz MR, Huynh P, Yang WT. Do all mucocele-like lesions of the breast require surgery? Clin Imaging 35(2):94-101, Mar-Apr, 3/2011. PMID: 21377046.
20. Brown AS, Hunt KK, Shen J, Huo L, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Boughey JC, Ching CD, Gilcrease MZ. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer 116(12):2878-83, 6/2010. PMID: 20564394.
21. Dogan BE, Gonzalez-Angulo AM, Gilcrease MZ, Dryden MJ, Yang WT. Multimodality imaging of triple receptor negative tumors with mammography, ultrasound, and MRI. AJR Am J Roentgenol 194(4):1160-6, 4/2010. PMID: 20308526.
22. Nguyen CV, Falcón-Escobedo R, Hunt KK, Nayeemuddin KM, Lester TR, Harrell RK, Bassett RL, Gilcrease MZ. Pleomorphic ductal carcinoma of the breast: predictors of decreased overall survival. Am J Surg Pathol 34(4):486-93, 4/2010. PMID: 20154588.
23. Morkowski JJ, Nguyen CV, Lin P, Farr M, Abraham SC, Gilcrease MZ, Moran CA, Wu Y. Rosai-Dorfman disease confined to the breast. Ann Diagn Pathol 14(2):81-7, 4/2010. PMID: 20227012.
24. Adrada B, Arribas E, Gilcrease M, Yang WT. Invasive micropapillary carcinoma of the breast: mammographic, sonographic, and MRI features. AJR 193(1):W58-63, 7/2009. PMID: 19542384.
25. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69(10). e-Pub 5/2009. PMCID: PMC2737191.
26. Gilcrease MZ, Woodward WA, Nicolas MM, Corley LJ, Fuller GN, Esteva FJ, Tucker SL, Buchholz TA. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol 33(5):759-67, 5/2009. NIHMSID: NIHMSNIHMS269613.
27. Huo L, Gilcrease MZ. Fibroepithelial lesions of the breast with pleomorphic stromal giant cells: a clinicopathologic study of 4 cases and review of the literature. Ann Diagn Pathol 13(4). e-Pub 5/2009. PMID: 19608080.
28. Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ. Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol 33(4):534-41, 4/2009. PMID: 19047898.
29. Khalifeh I, Deavers MT, Cristofanilli M, Coleman RL, Malpica A, Gilcrease MZ. Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. Breast J 15(2):176-81, Mar-Apr, 3/2009. PMID: 19292804.
30. Gilcrease MZ, Kilpatrick SK, Woodward WA, Zhou X, Nicolas MM, Corley LJ, Fuller GN, Tucker SL, Diaz LK, Buchholz TA, Frost JA. Coexpression of alpha6beta4 Integrin and Guanine Nucleotide Exchange Factor Net1 Identifies Node-Positive Breast Cancer Patients at High Risk for Distant Metastasis. Cancer Epidemiol Biomarkers Prev 18(1):80-6, 1/2009. PMCID: PMC2669542.
31. Gilcrease MZ, Zhou X, Lu X, Woodward WA, Hall BE, Jorrisey PJ. Alpha6beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer. J Exp Clin Cancer Res 28:67, 2009. PMCID: PMC2694164.
32. Yi M, Meric-Bernstam F, Akins JS, Hwang RF, Lucci A, Kuerer HM, Babiera GV, Gilcrease MZ, Hunt KK. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer 113(1):30-37, 2008. PMID: 18457326.
33. Yang WT, Dryden M, Broglio K, Dawood S, Valero V, Hortobagyi G, Dempsey PJ, Atchley D, Arun B, Gilcrease MZ. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 111(3):405-10, 2008. PMID: 18026834.
34. Yang WT, Hennessy B, Broglio K, Mills C, Sneige N, Davis WG, Valero V, Hunt KK, Gilcrease MZ. Imaging differences in metaplastic and invasive ductal carcinomas of the breast. AJR Am J Roentgenol 189(6):1288-93, 12/2007. PMID: 18029860.
35. Mazurek N, Sun YJ, Liu KF, Gilcrease MZ, Schober W, Nangia-Makker P, Raz A, Bresalier RS. Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells. J Biol Chem 282(29):21337-48, 7/2007. e-Pub 4/2007. PMID: 17420249.
36. Shen J, Gilcrease MZ, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Francis A, Ames FC, Hunt KK. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 109(7):1255-63, 4/2007. PMID: 17330229.
37. Izaddoost S, Boughey JC, Williams SA, Gilcrease MZ, Ames F. An Unusual Presentation of Locally Recurrent Breast Cancer: A Case Report. Breast Journal 13:294-296, 2007.
38. Hennessy BT, Gonzalez-Angulo AM, Kim E, Gilcrease MZ. Breast Carcinoma with Neuroendocrine Differentiation and Myocardial Metastases. Clinical Breast Cancer 7(11):892-894, 2007.
39. Gilcrease MZ. Integrin signaling in epithelial cells. Cancer Letters 247:1-25, 2007. PMID: 16725254.
40. Nicolas MM, Wu Y, Middleton LP, Gilcrease MZ,. Loss of Myoepithelium is Variable in Solid Papillary Carcinoma of the Breast. Histopathology 51:657-665, 2007.
41. Gilcrease MZ, Sahin A. Pathological evaluation of axillary sentinel lymph nodes in breast cancer. Methods Mol Med 120:113-25, 2006. PMID: 16491598.
42. Diaz LK, Cristofanilli M, Zhou X, Welch KL, Smith TL, Yang Y, Sneige N, Sahin AA, Gilcrease MZ. Beta4 integrin subunit gene expression in node-negative invasive breast carcinoma: correlation with tumor size and nuclear grade. Modern Pathology 18:1165-75, 2005. PMID: 15920552.
43. Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 11:3309-14, 2005. PMID: 15867228.
44. Davis WG, Hennessy B, Babiera G, Hunt K, Valero V, Buchholz TA, Sneige N, Gilcrease MZ. Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer. American Journal of Surgical Pathology 29:1456-63, 2005. PMID: 16224212.
45. Vigneswaran N, Wu J, Sacks P, Gilcrease M, Zacharias W. Microarray gene expression profiling of cell lines from primary and metastatic tongue squamous cell carcinoma: possible insights from emerging technology. Journal of Oral Pathology & Medicine 34:77-86, 2005. PMID: 15641986.
46. Erguvan-Dogan B, Dempsey PJ, Ayyar G, Gilcrease MZ. Radiologic pathologic conference of M. D. Anderson Cancer Center: Primary desmoid tumor (extraabdominal fibromatosis) of the breast. AJR 185:488-9, 2005. PMID: 16037525.
47. Gong Y, Gilcrease M, Sneige N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Modern Pathology 18:1015-21, 2005. PMID: 15861212.
48. Onn A, Choe du H, Herbst RS, Correa AM, Munden RF, Truong MT, Vaporciyan AA, Isobe T, Gilcrease MZ, Marom EM. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology 237:342-7, 2005. PMID: 16183941.
49. Gilcrease MZ, Zhou X, Welch K. Adhesion-independent alpha6beta4 integrin clustering is mediated by phosphatidylinositol 3-kinase. Cancer Research 64:7395-8, 2004. PMID: 15492261.
50. Diaz LK, Zhou X, Welch K, Sahin A, Gilcrease MZ. Chromogenic in situ hybridization for alpha6beta4 integrin in breast cancer: correlation with protein expression. Journal of Molecular Diagnostics 6:10-5, 2004. PMID: 14736821.
51. Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clinical Cancer Research 10:136-43, 2004. PMID: 14734462.
52. Diaz LK, Hunt K, Ames F, Meric F, Kuerer H, Babiera G, Ross M, Singletary E, Middleton LP, Symmans WF, Krishnamurthy S, Sahin A, Sneige N, Gilcrease MZ. Histologic localization of sentinel lymph node metastases in breast cancer. American Journal of Surgical Pathology 27:385-9, 2003. PMID: 12604895.
53. Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clinical Cancer Research 9:5652-9, 2003. PMID: 14654548.
54. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Tsukuda K, Sugio K, Shimizu N, Shimizu K, Lee H, Chen CY, Fong KM, Gilcrease M, Roth JA, Minna JD, Gazdar AF. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. International Journal of Cancer 103:153-60, 2003. PMID: 12455028.
55. Zhang X, Liu Y, Gilcrease MZ, Yuan XH, Clayman GL, Adler-Storthz K, Chen Z. A lymph node metastatic mouse model reveals alterations of metastasis-related gene expression in metastatic human oral carcinoma sublines selected from a poorly metastatic parental cell line. Cancer 95:1663-72, 2002. PMID: 12365014.
56. Toyooka S, Pass HI, Shivapurkar N, Fukuyama Y, Maruyama R, Toyooka KO, Gilcrease M, Farinas A, Minna JD, Gazdar AF. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Research 61:5727-30, 2001. PMID: 11479207.
57. Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, Cunnigham HT, Farinas AJ, Milchgrub S, Euhus DM, Gilcrease M, Herman J, Minna JD, Gazdar AF. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clinical Cancer Research 7:1998-2004, 2001. PMID: 11448917.
58. Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K, Brambilla E, Gilcrease M, Minna JD, Gazdar AF. DNA methylation profiles of lung tumors. Molecular Cancer Therapeutics 1:61-7, 2001. PMID: 12467239.
59. Liu Y, Gilcrease MZ, Henderson Y, Yuan XH, Clayman GL, Chen Z. Expression of protease-activated receptor 1 in oral squamous cell carcinoma. Cancer Letters 169:173-80, 2001. PMID: 11431106.
60. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD, Gazdar AF. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Research 61:4556-60, 2001. PMID: 11389090.
61. Gilcrease MZ, Niehans G. Adhesion of aspirated tumor cells to extracellular matrix proteins: a new methodology utilizing fine-needle aspiration. Cancer Cytopathology 90:102-10, 2000. PMID: 10794159.
62. Gilcrease MZ, Guzman-Paz M, Niehans G, Cherwitz D, McCarthy JB, Albores-Saavedra J. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer 86(11):2320-6, 12/1999. PMID: 10590373.
63. Nussenbaum B, Roland PS, Gilcrease MZ, Odell DS. Extra-articular synovial chondromatosis of the temporomandibular joint: pitfalls in diagnosis. Arch Otolaryngol Head Neck Surg 125(12):1394-7, 12/1999. PMID: 10604423.
64. Gilcrease MZ, Delgado R, Albores-Saavedra J. Intrasellar adenoid cystic carcinoma and papillary mucinous adenocarcinoma: two previously undescribed primary neoplasms at this site. Ann Diagn Pathol 3(3):141-7, 6/1999. PMID: 10359849.
65. Albores-Saavedra J, Gilcrease M. Glomus tumor of the uterine cervix. Int J Gynecol Pathol 18(1):69-72, 1/1999. PMID: 9891244.
66. Gilcrease MZ, Delgado R, Vuitch F, Albores-Saavedra J. Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison. Hum Pathol 29(12):1451-6, 12/1998. PMID: 9865832.
67. Gilcrease MZ, Sahin M, Perri RT, Nelson FS, Guzman-Paz M. Fine needle aspiration of signet-ring cell lymphoma. A case report with differential diagnostic considerations. Acta Cytol 42(6):1461-7, Nov-Dec, 11/1998. PMID: 9850663.
68. Gilcrease MZ, Guzman-Paz M, Froberg K, Pambuccian S. Salivary duct carcinoma. Is a specific diagnosis possible by fine needle aspiration cytology? Acta Cytol 42(6):1389-96, Nov-Dec, 11/1998. PMID: 9850648.
69. Gilcrease MZ, Delgado R, Albores-Saavedra J. Testicular Sertoli cell tumor with a heterologous sarcomatous component: immunohistochemical assessment of Sertoli cell differentiation. Arch Pathol Lab Med 122(10):907-11, 10/1998. PMID: 9786352.
70. Gilcrease MZ, Guzman-Paz M. Fine-needle aspiration of basaloid squamous carcinoma: a case report with review of differential diagnostic considerations. Diagn Cytopathol 19(3):210-5, 9/1998. PMID: 9740998.
71. Gilcrease MZ, Nelson FS, Guzman-Paz M. Tyrosine-rich crystals associated with oncocytic salivary gland neoplasms. Arch Pathol Lab Med 122(7):644-9, 7/1998. PMID: 9674547.
72. Gilcrease MZ. Minimal residual cancer. Am J Surg Pathol 21(12):1524-5, 12/1997. PMID: 9414200.
73. Gilcrease MZ, Rajan B, Ostrowski ML, Ramzy I, Schwartz MR. Localized thymic Langerhans' cell histiocytosis and its relationship with myasthenia gravis: Immunohistochemical, ultrastructural, and cytometric studies. Arch Pathol Lab Med 121(2):134-8, 2/1997. PMID: 9126040.
74. Gilcrease MZ, Truong L, Brown RW. Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas. Hum Pathol 27(12):1355-60, 12/1996. PMID: 8958311.
75. Gilcrease MZ, Schmidt L, Zbar B, Truong L, Rutledge M, Wheeler TM. Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis. Hum Pathol 26(12):1341-6, 12/1995. PMID: 8522307.
76. Gilcrease MZ, Brandt ML, Hawkins EP. Yolk sac tumor identified at autopsy after surgical excision of immature sacrococcygeal teratoma. J Pediatr Surg 30(6):875-7, 6/1995. PMID: 7666328.
77. Gilcrease MZ, Hoover RL. Secretion of a chemotactic substance(s) by AGE-stimulated human monocytes. Diabetes Res Clin Pract 16(1):7-11, 4/1992. PMID: 1576934.
78. Gilcrease MZ, Hoover RL. Human monocyte interactions with non-enzymatically glycated collagen. Diabetologia 35(2):160-4, 2/1992. PMID: 1547921.
79. Gilcrease MZ, Hoover RL. Examination of monocyte adherence to endothelium under hyperglycemic conditions. Am J Pathol 139(5):1089-97, 11/1991. PMCID: PMC1886347.
80. Gilcrease MZ, Hoover RL. Neutrophil adhesion to endothelium following hyperosmolar insult. Diabetes Res 16(4):149-57, 4/1991. PMID: 1802480.
81. Gilcrease MZ, Hoover RL. Activated human monocytes exhibit receptor-mediated adhesion to a non-enzymatically glycosylated protein substrate. Diabetologia 33(6):329-33, 6/1990. PMID: 2165945.
82. Gilcrease MZ, Hoover RL. Adhesion of activated human monocytes to a non-enzymatically glycosylated protein substrate. Diabetologia 33:329-333, 1990.

Invited Articles

1. Gilcrease MZ. Breast cancer prognostic and predictive biomarkers. In: Encyclopedia of Cancer, 3rd Edition (M. Schwab, ed.) Springer-Verlag, Heidelberg, Germany, 2012.
2. Gilcrease MZ. Integrin signaling in cancer. In: M. Schwab, ed. Encyclopedia of Cancer, 2nd edition, Heidelberg, Germany: Springer-Verlag:1547-49, 2009.
3. Gilcrease MZ. Invasion. In: M. Schwab, ed. Encyclopedia of Cancer, 2nd edition, Heidelberg, Germany: Springer-Verlag:1564-66, 2009.
4. Gilcrease MZ, Sahin AA. Detection of ductal carcinoma in situ by screening mammography: pathologic features important for clinical management. Breast Diseases: A Yearbook Quarterly 13(4):316-323, 2003.

Editorials

1. Gilcrease MZ. Is Immunohistochemical Analysis of Sentinel Lymph Nodes Obsolete? Breast Diseases: A Year Book Quarterly 22(3):237-8, 2011.
2. Gilcrease MZ. Review of Masood S, Cytopathology of the Breast, Chicago, IL, American Society of Clinical Pathologists. Human Pathol 28:389-390, 1997.
Other Articles
1. Gilcrease MZ. Commentary on Rakha EA, et al. Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. (Br J Cancer 112:283-9, 2015). Breast Diseases: A Year Book Quarterly. In Press.
2. Gilcrease MZ. Commentary on Ni Y-B, et al. A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma. (Ann Surg Oncol 21:2928-33, 2014). Breast Diseases: A Year Book Quarterly 26(2):142-3, 2015.
3. Gilcrease MZ. Commentary on Biglia N et al. Clinical-pathologic features, long term outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). (Eur J Surg Oncol 39:455-60, 2013). Breast Diseases: A Year Book Quarterly 24(4):348-9, 2014.
4. Gilcrease MZ. Commentary on Garrison Jr., LP et al. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status. (Cancer 119:3113-22, 2013). Breast Diseases; A Year Book Quarterly 25(1):93-4, 2014.
5. Gilcrease MZ. Commentary on Karlsson E, et al. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events. (Eur J Cancer 50:517-24, 2014). Breast Diseases: A Year Book Quarterly 25(3):237-8, 2014.
6. Gilcrease MZ. Commentary on Tsang JYS, et al. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers. (Ann Surg Oncol 21:2218-28, 2014). Breast Diseases: A Year Book Quarterly 25(4):311-12, 2014.
7. Gilcrease MZ. Controversies Regarding Breast Margin Assessment. Society of Breast Imaging Newsletter(4), 2014.
8. Gilcrease MZ. Commentary on Gonzalez-Angulo AM, et al. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. (Cancer 119:7-15, 2013). Breast Diseases: A Year Book Quarterly 24(3):242-3, 2013.
9. Gicrease MZ. Commentary on Morrison DH, et al. Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer. (Br J Cancer 107(2):382-7, 2012). Breast Diseases: A Year Book Quarterly 24(1):38-9, 2013.
10. Gilcrease MZ. Commentary on Saadatmand S, et al. Expression of cell adhesion molecules and prognosis in breast cancer. (Br J Surgery 100:252-60, 2013). Breast Diseases: A Year Book Quarterly 24(3):247-8, 2013.
11. Gilcrease MZ. Commentary on Aktas B, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. (Gynecol Oncol 122(2):356-60, 2011). Breast Diseases: A Year Book Quarterly 23(3):244-6, 2012.
12. Gilcrease MZ. Commentary on Fabi A, et al. HER2 protein and gene variation between primary and metastatic breast cancer: Significance and impact on patient care. (Clin Cancer Res 17:2055-64, 2011). Breast Diseases: A Year Book Quarterly 23(2):157-8, 2012.
13. Gilcrease MZ. Commentary on Kashiwagi S, et al. Significance of E-cadherin expression in triple-negative breast cancer. (Br J Cancer 103:249-55, 2010). Breast Diseases: A Year Book Quarterly 22(1):54-6, 2011.
14. Gilcrease MZ. Commentary on Querzoli P, et al. An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. (Br J Cancer 103:1835-9, 2010). Breast Diseases: A Year Book Quarterly 22(3):273-4, 2011.
15. Gilcrease MZ. Commentary on Capodanno A, et al. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. (Hum Pathol 40:1408-17, 2009). Breast Diseases: A Year Book Quarterly 21(1):47-8, 2010.
16. Gilcrease MZ. Commentary on Finn RS, et al. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. (J Clin Oncol 27:5552-8, 2009). Breast Diseases: A Year Book Quarterly 21(4):337-8, 2010.
17. Gilcrease MZ. Commentary on Grabowski J, et al. Squamous cell carcinoma of the breast: a review of 177 cases. (Am Surg 75:914-7, 2009). Breast Diseases: A Year Book Quarterly 21:146-7, 2010.
18. Gilcrease MZ. Commentary on Hammond EH, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (Arch Pathol Lab Med 134:907-22, 2010). Breast Diseases: A Year Book Quarterly 21(4):336-7, 2010.
19. Gilcrease MZ. Commentary on Rakha EA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal types. (Clin Cancer Res 15:2302-10, 2009). Breast Diseases: A Year Book Quarterly 20:405-6, 2010.
20. Gilcrease MZ. Commentary on Alkuwari E, et al. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients: a study of 115 cases with cytologic-histologic correlation. (Cancer 114:89-93, 2008). Breast Diseases: A Year Book Quarterly 20:61-2, 2009.
21. Gilcrease MZ. Commentary on Bleicher RJ, et al. A prospective feasibility trial to determine the significance of the sentinel node gradient in breast cancer: a predictor of nodal metastasis location. (Cancer 113:3100-7, 2008). Breast Diseases: A Year Book Quarterly 20:190-1, 2009.
22. Gilcrease MZ. Commentary on Riedl O, et al. Intraoperative frozen section analysis for breast-conserving therapy in 1016 patients with breast cancer. (Eur J Surg Oncol 35:264-70, 2009). Breast Diseases: A Year Book Quarterly 20:288-9, 2009.
23. Gilcrease MZ. Commentary on de Azambuja E, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. (Br J Cancer 96:1504-13, 2007). Breast Diseases: A Year Book Quarterly 19:51-52, 2008.
24. Gilcrease MZ. Commentary on Hameed O, et al. Does using a higher cutoff for the percentage of positive cells improve the specificity of HER2 immunohistochemical analysis in breast carcinoma? (Am J Clin Pathol 128:825-9, 2007). Breast Diseases: A Year Book Quarterly 19:143-144, 2008.
25. Gilcrease MZ. Commentary on Hanley K, et al. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. (Hum Pathol 39:386-92, 2008). Breast Diseases: A Year Book Quarterly 19:221, 2008.
26. Gilcrease MZ. Commentary on Karabakhtsian RG, et al. The clinical significance of lobular neoplasia on breast core biopsy. (Am J Surg Pathol 31:717, 2007). Breast Diseases: A Year Book Quarterly 18:368-369, 2008.
27. Gilcrease MZ. Commentary on Penault-Llorca F, et al. Comparison of the Prognostic Significance of Chevallier and Sataloff’s Pathologic Classifications after Neoadjuvant Chemotherapy of Operable Breast Cancer. (Hum Pathol 39:1221-8, 2008). Breast Diseases: A Year Book Quarterly 19:352-3, 2008.
28. Gilcrease MZ. Commentary on Wright MJ, et al. Perpendicular inked versus tangential shaved margins in breast-conserving surgery: Does the method matter? (J Am Coll Surg 204:541-9, 2007). Breast Diseases: A Year Book Quarterly 18:383-384, 2008.
29. Gilcrease MZ. Commentary on Apple SK. Variability in gross and microscopic pathology reporting in excisional biopsies of breast cancer tissue. (Breast J 12:145-9, 2006). Breast Diseases: A Year Book Quarterly 17:371, 2007.
30. Gilcrease MZ. Commentary on Bleiweiss IJ, et al. Axillary sentinel lymph nodes can be falsely positive due to latrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. (J Clin Oncol 24:2013-8, 2006). Breast Diseases: A Year Book Quarterly 18:65, 2007.
31. Gilcrease MZ. Commentary on Kong SY, et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. (Clin Chem 52:1510-5, 2006). Breast Diseases: A Year Book Quarterly 18:63-64, 2007.
32. Gilcrease MZ. Commentary on Van den Eynden GG, et al. Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer. (Br J Cancer 95:1362-6, 2006). Breast Diseases: A Year Book Quarterly 18:272-273, 2007.
33. Gilcrease MZ. Commentary on Jacobs TW, et al. Fibroepithelial lesions with cellular stroma on breast core needle biopsy: Are there predictors of outcome on surgical excision? (Am J Clin Pathol 124:342-54, 2005). Breast Diseases: A Year Book Quarterly 17:57-58, 2006.
34. Gilcrease MZ. Commentary on Kim MJ, et al. Immunohistochemical and clinicopathologic characteristics of invasive ductal carcinoma of breast with micropapillary carcinoma component. (Arch Pathol Lab Med 129:1277-82, 2005). Breast Diseases: A Year Book Quarterly 17:154, 2006.
35. Gilcrease MZ. Commentary on Mercado CL, et al. Papillary lesions of the breast at percutaneous core-needle biopsy. (Radiology 238:801-8, 2006). Breast Diseases: A Year Book Quarterly 17:240, 2006.
36. Gilcrease MZ. Commentary on Agoff SN, et al. Papillary lesions of the breast with and without atypical ductal hyperplasia: can we accurately predict benign behavior from core needle biopsy? (Am J Clin Pathol 122:440-3, 2004). Breast Diseases: A Year Book Quarterly 16:50, 2005.
37. Gilcrease MZ. Commentary on Fortunato L, et al. Intraoperative examination of sentinel nodes in breast cancer: is the glass half full or half empty. (Ann Surg Oncol 11:1005-10, 2004). Breast Diseases: A Year Book Quarterly 16:174, 2005.
38. Gilcrease MZ. Commentary on Hermsen BB, et al. Lobulitis is a frequent finding in prophylactically removed breast tissue from women at hereditary highrisk of breast cancer. (J Pathol 206:220-3, 2005). Breast Diseases: A Year Book Quarterly 16:359, 2005.
39. Gilcrease MZ. Commentary on Klepchick PR, et al. Selective intraoperative consultation for the evaluation of sentinel lymph nodes in breast cancer. (Am J Surg 188:429-32, 2004). Breast Diseases: A Year Book Quarterly 16:158-159, 2005.
40. Gilcrease MZ. Commentary on Lal P, et al. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. (Am J Clin Pathol 123:541-6, 2005). Breast Diseases: A Year Book Quarterly 16:356, 2005.
41. Gilcrease MZ. Commentary on Lundin M, et al. A digital atlas of breast histopathology: an application of web-based virtual microscopy. (J Clin Pathol 57:1288-91, 2004). Breast Diseases: A Year Book Quarterly 16:238, 2005.
42. Gilcrease MZ. Commentary on Volpi A, et al. Prognostic relevance of histological grade and its components in node-negative breast cancer patients. (Mod Pathol 17:1038-44, 2004). Breast Diseases: A Year Book Quarterly 16:49-50, 2005.
43. Gilcrease MZ. Commentary on Munakata S, et al. Application of immunofluorescence for intraoperative evaluation of sentinel lymph nodes in patients with breast carcinoma. (Cancer 98:1562-8, 2003). Breast Diseases: A Year Book Quarterly 15:162, 2004.
44. Gilcrease MZ. Commentary on Span PN, et al. Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival. (J Clin Oncol 22:691-8, 2004). Breast Diseases: A Year Book Quarterly 16:280, 2004.
45. Gilcrease MZ. Commentary on Weaver DL, et al. Comparison of pathologist-detected and automated computer-assisted image analysis detected sentinel lymph node micrometastases in breast cancer. (Mod Pathol 16:1159-63, 2003). Breast Diseases: A Year Book Quarterly 15:156, 2004.
46. Gilcrease MZ. Commentary on Bratthauer GL, et al. Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias. (Hum Pathol 33:620-7, 2002). Breast Diseases: A Year Book Quarterly 14:50, 2003.
47. Gilcrease MZ. Commentary on Causon JN, et al. Fourteen-guage needle core biopsy of mammographically evident radial scars: is excision necessary? (Cancer 97:345-51, 2003). Breast Diseases: A Year Book Quarterly 14:173-174, 2003.
48. Gilcrease MZ. Commentary on Grownendijk RP, et al. Mitotic activity index in interval breast cancers. (Eur J Surg Oncol 29:29-31, 2003). Breast Diseases: A Year Book Quarterly 14:293, 2003.
49. Gilcrease MZ. Commentary on Grube BJ, et al. Tumor characteristics predictive of sentinel node metastases in 105 consecutive patients with invasive lobular carcinoma. (Am J Surg 184:372-6, 2002). Breast Diseases: A Year Book Quarterly 14:199, 2003.
50. Gilcrease MZ. Commentary on Irfan K, et al. Surgical and mammographic follow-up of papillary lesions and atypical lobular hyperplasia diagnosed with stereotactic vacuum-assisted biopsy" and "Lobular neoplasia in breast core needle biopsy specimens is not associated with an increased risk of ductal carcinoma in situ or invasive carcinoma. (Breast J 8:230-3, 2002). Breast Diseases: A Year Book Quarterly 14:47-48, 2003.
51. Gilcrease MZ. Commentary on van de Rijn M, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. (Am J Pathol 161:1991-6, 2002). Breast Diseases: A Year Book Quarterly 14:173-174, 2003.
52. Gilcrease MZ. Commentary on Wahed A, et al. E-cadherin expression in pleomorphic lobular carcinoma: an aid to differentiation from ductal carcinoma. (Ann Diagn Pathol 6:349-51, 2002). Breast Diseases: A Year Book Quarterly 14:297, 2003.
53. Gilcrease MZ. Commentary on Werling RW, et al. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smoth muscle myosin heavy chain. (Am J Surg Pathol 27:82-90, 2003). Breast Diseases: A Year Book Quarterly 14:295, 2003.

Book Chapters

1. Gilcrease MZ. Breast pathology. In: Diagnostic Imaging: Breast, 2nd Edition. Ed(s) W Berg, W Yang. Amirsys: Salt Lake City, UT, 9.70-9.75, 2013.
2. Moulder SL, Hennessy BT, Gilcrease MZ, Barbiera G, Yang W, Valero V, Hortobagyi GN. Carcinosarcoma of the breast. In: Textbook of Uncommon Cancer, 4th Edition. Ed(s) D Raghavan, ML Brecher, DH Johnson, NJ Meropol, PL Moots, PG Rose, IA Mayer. John Wiley & Sons, Ltd. West Sussex, UK, 257-69, 2012.
3. Gilcrease MZ, Babiera GV, Hennessy BT, Woodward WA. Metaplastic carcinoma of the breast. In: Advanced Therapy of Breast Disease, 3rd Edition. Ed(s) Babiera GV, Skoracki RJ, Esteva FJ. B. C. Decker: Lewiston, New York, 1119-32, 2012.
4. Hennessy BT, Gilcrease MZ, Barbiera G, Yang W, Valero V, Hortobagyi GN. Carcinosarcoma of the breast. In: Textbook of Uncommon Cancer, 3rd Edition. Ed(s) D Raghavan, ML Brecher, DH Johnson, NJ Meropol, PL Moots, PG Rose, IA Mayer. John Wiley & Sons, Ltd. West Sussex, UK, 2006.
5. Gilcrease MZ, Sahin AA. Pathologic evaluation of axillary sentinel lymph nodes in breast cancer. In: Breast Cancer Research Protocols. Ed(s) S Brooks, A Harris. Humana Press, 113-125, 2006.
6. Albores-Saavedra, J, Gilcrease MZ, Henson DE:. Uterine cervix. In: Pathology of Incipient Neoplasia, 3rd Edition. Oxford University Press,, 376-400, 2001.

Letters to the Editor

1. Gilcrease MZ. No benefit to intraoperative assessment of breast margins? Am J Clin Pathol 140(4):597, 10/2013. PMID: 24045560.
2. Albarracin C, Edgerton ME, Gilcrease MZ, Huo L, Krishnamurthy S, Middleton LP, Resetkova E, Sahin AA, Sneige N, Fraser WS, Wu Y. Is it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med 134(2):162-3, 2/2010. PMID: 20121597.
3. Downs-Kelly E, Gilcrease MZ. Matrix-producing carcinoma: just another triple-negative breast cancer? Am J Surg Pathol 34(1):125-6, 2010.
4. Diaz LK, Gilcrease MZ. A Prospective Feasibility Trial to Determine the Significance of the Sentinel Node Gradient in Breast Cancer: A Predictor of Nodal Metastasis Location. Cancer 115(24):5845, 12/2009. PMID: 19806639.
5. Gilcrease MZ. Reply to: HER2 intermediate breast cancers. Am J Surg Pathol 33(11):1739-40, 2009.
6. Gilcrease MZ. Sarcomatoid breast tumors have sarcomatoid behavior. Am J Surg Pathol 31:326-7; author reply 327, 2007. PMID: 17255781.
7. Davis WG, Gilcrease MZ. On clinically meaningful terminology for sarcomatoid tumors of the breast. Am J Surg Pathol 30:1053-1055, 2006.
8. Diaz LK, Gilcrease MZ. Reply to Gabor Cserni re: Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol 28:275-6, 2004.
9. Gilcrease MZ. Nontyrosine crystalloids? Diagn Cytopathol 22:60, 2000.
10. Gilcrease MZ. Minimal residual (prostate) cancer. Am J Surg Pathol 21:1524-1525, 1997.

Last updated: 7/29/2015